Pfizer Inks Manufacturing Deals with Samsung Biologics Worth Nearly $900M

Pfizer signed two strategic agreements Tuesday, designating South Korea’s Samsung Biologics as a contract manufacturing partner for biosimilar products, according to an article by The Korea Times.